NO20015446L - Kinolin-derivater som inhibitorer for MEK-enzymer - Google Patents
Kinolin-derivater som inhibitorer for MEK-enzymerInfo
- Publication number
- NO20015446L NO20015446L NO20015446A NO20015446A NO20015446L NO 20015446 L NO20015446 L NO 20015446L NO 20015446 A NO20015446 A NO 20015446A NO 20015446 A NO20015446 A NO 20015446A NO 20015446 L NO20015446 L NO 20015446L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- group
- optionally
- carbon
- various
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9910579.3A GB9910579D0 (en) | 1999-05-08 | 1999-05-08 | Chemical compounds |
PCT/GB2000/001707 WO2000068200A1 (en) | 1999-05-08 | 2000-05-03 | Quinoline derivatives as inhibitors of mek enzymes |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20015446D0 NO20015446D0 (no) | 2001-11-07 |
NO20015446L true NO20015446L (no) | 2001-12-12 |
Family
ID=10852988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20015446A NO20015446L (no) | 1999-05-08 | 2001-11-07 | Kinolin-derivater som inhibitorer for MEK-enzymer |
Country Status (17)
Country | Link |
---|---|
US (1) | US6809106B1 (no) |
EP (1) | EP1178966B1 (no) |
JP (1) | JP2002544195A (no) |
KR (1) | KR20010110810A (no) |
CN (1) | CN1352635A (no) |
AT (1) | ATE252561T1 (no) |
AU (1) | AU4589700A (no) |
BR (1) | BR0010324A (no) |
CA (1) | CA2370838A1 (no) |
DE (1) | DE60006099T2 (no) |
GB (1) | GB9910579D0 (no) |
IL (1) | IL146326A0 (no) |
NO (1) | NO20015446L (no) |
NZ (1) | NZ514814A (no) |
TR (1) | TR200103184T2 (no) |
WO (1) | WO2000068200A1 (no) |
ZA (1) | ZA200108965B (no) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036570A1 (en) | 2000-11-02 | 2002-05-10 | Astrazeneca Ab | 4-substituted quinolines as antitumor agents |
WO2002044166A1 (en) | 2000-11-02 | 2002-06-06 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
EP1633718B1 (en) * | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
US20050171182A1 (en) * | 2003-12-11 | 2005-08-04 | Roger Briesewitz | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
EP2025347A4 (en) | 2006-05-15 | 2010-08-11 | Takeda Pharmaceutical | PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER |
ATE478847T1 (de) * | 2006-09-15 | 2010-09-15 | Pfizer | Substituierte pyridylmethylbicyclocarboxyamidverbindungen |
KR20090130347A (ko) * | 2007-05-09 | 2009-12-22 | 화이자 인코포레이티드 | 치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도 |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA2928658A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US20160340407A1 (en) | 2014-01-14 | 2016-11-24 | Dana-Farber Camcer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
CN104860869B (zh) * | 2015-04-03 | 2017-11-03 | 北京大学 | 具有mek激酶抑制功能的化合物及其制备方法与应用 |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
EP3359526A4 (en) | 2015-10-05 | 2019-04-03 | The Trustees of Columbia University in the City of New York | ACTIVATORS OF AUTOPHAGIC FLOW AND PHOSPHOLIPASE D AND CLAIRANCE OF PROTEIN AGGREGATES COMPRISING TAU AND TREATMENT OF PROTEINEOPATHIES |
AU2017324251A1 (en) | 2016-09-08 | 2019-03-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE317376B (no) | 1961-07-10 | 1969-11-17 | Roussel Uclaf | |
FR2077455A1 (en) | 1969-09-03 | 1971-10-29 | Aries Robert | 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials |
US3936461A (en) | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
FR2498187A1 (fr) | 1981-01-16 | 1982-07-23 | Rhone Poulenc Sante | Procede de preparation d'amino-4 chloro-7 quinoleines |
IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
US4743601A (en) * | 1987-07-13 | 1988-05-10 | Hoechst-Roussel Pharmaceuticals Inc. | Dihydro-1,4-oxazino(2,3-C)quinolines |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
CA2114727C (en) | 1991-08-02 | 1996-12-10 | Mikel P. Moyer | Quinoline derivatives as immunostimulants |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
DE69733825T2 (de) | 1996-09-25 | 2006-06-08 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
CA2290509A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
JP4537582B2 (ja) | 1998-09-29 | 2010-09-01 | アメリカン・サイアナミド・カンパニー | プロテインチロシンキナーゼインヒビターとしての置換3−シアノキノリン |
NZ510551A (en) | 1998-09-29 | 2003-03-28 | American Cyanamid Co | Substituted 3-cyanoquinolines useful as protein tyrosine kinases inhibitors |
-
1999
- 1999-05-08 GB GBGB9910579.3A patent/GB9910579D0/en not_active Ceased
-
2000
- 2000-05-03 AT AT00927497T patent/ATE252561T1/de not_active IP Right Cessation
- 2000-05-03 BR BR0010324-1A patent/BR0010324A/pt not_active IP Right Cessation
- 2000-05-03 WO PCT/GB2000/001707 patent/WO2000068200A1/en not_active Application Discontinuation
- 2000-05-03 CA CA002370838A patent/CA2370838A1/en not_active Abandoned
- 2000-05-03 US US09/959,005 patent/US6809106B1/en not_active Expired - Fee Related
- 2000-05-03 KR KR1020017014190A patent/KR20010110810A/ko not_active Application Discontinuation
- 2000-05-03 CN CN00807282A patent/CN1352635A/zh active Pending
- 2000-05-03 TR TR2001/03184T patent/TR200103184T2/xx unknown
- 2000-05-03 DE DE60006099T patent/DE60006099T2/de not_active Expired - Fee Related
- 2000-05-03 IL IL14632600A patent/IL146326A0/xx unknown
- 2000-05-03 JP JP2000617180A patent/JP2002544195A/ja active Pending
- 2000-05-03 EP EP00927497A patent/EP1178966B1/en not_active Expired - Lifetime
- 2000-05-03 NZ NZ514814A patent/NZ514814A/en unknown
- 2000-05-03 AU AU45897/00A patent/AU4589700A/en not_active Abandoned
-
2001
- 2001-10-30 ZA ZA200108965A patent/ZA200108965B/en unknown
- 2001-11-07 NO NO20015446A patent/NO20015446L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200108965B (en) | 2003-01-30 |
DE60006099T2 (de) | 2004-07-08 |
JP2002544195A (ja) | 2002-12-24 |
EP1178966A1 (en) | 2002-02-13 |
CA2370838A1 (en) | 2000-11-16 |
NO20015446D0 (no) | 2001-11-07 |
KR20010110810A (ko) | 2001-12-13 |
BR0010324A (pt) | 2002-01-08 |
TR200103184T2 (tr) | 2002-03-21 |
WO2000068200A1 (en) | 2000-11-16 |
GB9910579D0 (en) | 1999-07-07 |
NZ514814A (en) | 2003-10-31 |
CN1352635A (zh) | 2002-06-05 |
IL146326A0 (en) | 2002-07-25 |
DE60006099D1 (de) | 2003-11-27 |
EP1178966B1 (en) | 2003-10-22 |
ATE252561T1 (de) | 2003-11-15 |
AU4589700A (en) | 2000-11-21 |
US6809106B1 (en) | 2004-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20015446D0 (no) | Kinolin-derivater som inhibitorer for MEK-enzymer | |
NO20015447D0 (no) | Kinolinderivater som inhibitorer av MEK enzymer | |
NO20015448D0 (no) | Kinolinderivater som inhibitorer av MEK enzymer | |
HUP0104816A2 (hu) | 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra | |
RU95108387A (ru) | Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина | |
FI863564A0 (fi) | Foerfarande foer framstaellning av heterocykliskt substituerade indoler. | |
FI942635A (fi) | Piperatsiinijohdannaiset 5HT1A-antagonisteina | |
ATE25682T1 (de) | Indol-3-carboxamid-derivate. | |
HUP9903836A2 (hu) | Új eljárás Cox-2 inhibítor hatású fenil-szubsztituált 2(5H)-furanonok előállítására | |
ATE497948T1 (de) | Bicyclische verbindungen | |
IL98681A (en) | Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives | |
FI860117A (fi) | Nya derivat av pristinamycin iib och deras framstaellning. | |
FI914910A (fi) | Heterocykliska foereningar. | |
HUP0303457A2 (hu) | Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk | |
KR910021376A (ko) | 6-치환된-헥사하이드로벤즈[cd]인돌 | |
WO1999055156A3 (de) | Verwendung von derivaten des iminotriazols als pflanzenschutzmittel und neue iminotriazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |